Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Authors:
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 66 (1) , 31-44
Abstract
Objective. Mycophenolic acid (MPA) exerts its immunosuppression by inhibiting inosine 5′‐monophosphate dehydrogenase (IMPDH), depleting activated lymphocytes of guanine nucleotides and retarding their proliferation. An optimal strategy for monitoring has not been established for mycophenolate mofetil (MMF) in renal transplantation, and clinical investigations of the pharmacokinetic‐pharmacodynamic relationship are warranted. Material and methods. Mycophenolic acid pharmacokinetics and whole blood cell IMPDH activity were investigated in two separate groups of renal allograft recipients. One group was studied within the 12‐h dose interval, while the second group was examined by pre‐dose samples pre‐transplant and then repeatedly during 8 weeks post‐transplant. Results. An inverse relationship between plasma MPA and IMPDH activity within the dose interval was demonstrated. Minimum IMPDH activity was a median 8 % of values pre‐MMF dose, coinciding with the MPA peak. Six hours post‐dose, IMPDH activity had returned to pre‐dose values. Patients receiving MMF had a 4.5‐fold higher pre‐dose enzyme activity than transplanted patients without MMF. During the 8 weeks post‐transplant, the median MPA trough concentration was fairly stable. Following an initial decrease during the first 4 days post‐transplant, IMPDH activity gradually increased during the 40 days post‐transplant, reaching 5‐fold the pre‐transplant values. Conclusions. Provided that the changes in IMPDH activity in whole blood cells predict the clinical effect, these pharmacokinetic‐pharmacodynamic findings may prove useful in the attempts to identify optimal timing and range for the monitoring of mycophenolate in renal transplantation. The question of whether MPA concentrations or measurements of IMPDH activity per se will be the optimal way of monitoring this immunosuppressant remains open and will only be answered by prospective clinical testing.Keywords
This publication has 25 references indexed in Scilit:
- Pre-Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal TransplantationAmerican Journal of Transplantation, 2004
- Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trialThe Lancet, 2004
- TDM: Report Concentration, &OV0488;ss, Rather Than Area under the Curve, AUCTherapeutic Drug Monitoring, 2003
- Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipientsClinical Pharmacology & Therapeutics, 2001
- Transcriptional Regulation of the Yeast GMP Synthesis Pathway by Its End ProductsJournal of Biological Chemistry, 2001
- A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1Transplantation, 1999
- Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetilClinical Pharmacology & Therapeutics, 1999
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- PHARMACODYNAMIC ASSESSMENT OF MYCOPHENOLIC ACIDINDUCED IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1996
- Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high performance liquid chromatography linked methodClinica Chimica Acta, 1995